plasmablastic lymphoma (Cancer)
Information
- Disease name
- plasmablastic lymphoma
- Disease ID
- DOID:0080779
- Description
- "A large B-cell lymphoma that is characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells." [url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467349/, url:https\://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430862/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02481310 | Active, not recruiting | Phase 1/Phase 2 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | October 28, 2015 | July 2024 |
| NCT02797470 | Active, not recruiting | Phase 1/Phase 2 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | June 23, 2016 | June 30, 2025 |
| NCT03038672 | Active, not recruiting | Phase 2 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | December 21, 2018 | October 25, 2024 |
| NCT01193842 | Completed | Phase 1/Phase 2 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | October 6, 2010 | May 19, 2022 |
| NCT01092182 | Completed | Phase 2 | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma | March 25, 2010 | February 16, 2023 |
| NCT05663502 | Recruiting | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | May 10, 2023 | August 31, 2035 | |
| NCT04139304 | Recruiting | Early Phase 1 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | May 24, 2021 | August 2027 |
| NCT04915248 | Recruiting | Phase 2 | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. | July 11, 2022 | June 1, 2024 |
| NCT05389423 | Recruiting | Phase 1 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | June 27, 2023 | June 1, 2032 |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
- Disase is a (Disease Ontology)
- DOID:0081452
- Cross Reference ID (Disease Ontology)
- ICDO:9735/3
- Cross Reference ID (Disease Ontology)
- MESH:D000069293
- Cross Reference ID (Disease Ontology)
- NCI:C7224
- MeSH unique ID (MeSH (Medical Subject Headings))
- D000069293